Method Profile
Kidney and vascular features are measured across scaffold, matrix and flow conditions, with tacrolimus used for an injury demonstration.
Evaluation of culture conditions that support vascular structures while retaining nephron-like morphology.
One hiPSC-derived nephron-progenitor-enriched population combined with human stromal vascular fraction cells and collagen scaffolds; porcine decellularized kidney matrix is optional.
Static, 0.01 mL/min and 0.47 mL/min culture comparisons; drug exposure in suspension organoids and selected scaffold/co-culture configurations.
Tissue and vascular support
Kidney organoids, stromal vascular fraction cells, collagen sponges and optional kidney dECM.
Measurement systems
CD31/PODXL/KIM-1 staining, vessel-network analysis and LDH-associated cytotoxicity.
Analyze tissue structure and vascular metrics separately. The suspension-organoid LDH dose response and normalized scaffold-culture measurements belong to different experimental configurations.
Compare support conditions and test tacrolimus injury over 24 hours.
One hiPSC line and one drug. Suspension-organoid LDH dose response: N = 2 biological replicates with n = 3 samples. SVF-scaffold-only LDH comparison: N = 1 with n = 2 samples. Sampling differs between configurations.
Suspension/static culture, presence or absence of SVF/dECM, alternative flow rates and untreated controls.
Lower flow better preserved kidney architecture; higher flow disrupted it. The suspension-organoid tacrolimus CC50 was 70.87 μM. SVF-only vascularized scaffolds showed about 3% cytotoxicity across 0–100 μM, while organoid-containing co-cultures showed tissue and vascular injury at 70 μM.
A study combines kidney organoids, vascular-supporting cells and collagen scaffolds to compare perfusion conditions. Lower flow preserved nephron-like architecture, while separate tacrolimus experiments measured tissue and vascular injury.
